Patients undergoing hemodialysis. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: 26 patients in the intervention group will receive probiotic capsules (manufactured by Takgene Pharmaceutical Company) twice daily for 3 months. The patient will be
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Over 18 years old Patient consent to participate in the study Have been undergoing regular hemodialysis for at least 6 months Undergo hemodialysis at least twice a week.
Exclusion criteria
Exclusion criteria: Patients' unwillingness to participate in the study Alcohol consumption Pregnancy and lactation Sensitivity or allergy to probiotics Taking any other probiotic supplements Taking any anti-inflammatory medication Antibiotics taken within the last 2 weeks Active infection or recent hospitalization Co-occurrence of malignancies and autoimmune diseases Transplant recipient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of probiotic supplementation on NLR. Timepoint: At the beginning of the study, 30, 60 and 90 days after starting use. Method of measurement: Blood sample.;Effect of probiotic supplementation on PLR. Timepoint: At the beginning of the study, 30, 60 and 90 days after starting use. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the beginning and end of the study. Method of measurement: Weighing scale.;Complete blood count (CBC). Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Sodium. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Potassium. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Aspartate aminotransferase (AST). Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Alanine aminotransferase (ALT). Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Cholestrol. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Triglycerides. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;High-density lipoprotein (HDL). Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Low-density lipoprotein (LDL). Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Albumin. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Phosphorus. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Calcium. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sample.;Magnesium. Timepoint: At the beginning of the study, 30, 60 and 90 days after the start of the study. Method of measurement: Blood sam | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShadi Ziaie Ardestani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed